Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Schistosome Tegument-Allergen-Like (TAL) protein family is a group of calcium-binding proteins found exclusively in parasitic flatworms, including Schistosoma mansoni, S. haematobium, and S. japonicum [2, 4, 10]. These proteins are characterized by a conserved structure featuring two N-terminal EF-hand motifs and a C-terminal dynein light chain (DLC)-1 domain [3, 5, 6]. They are primarily localized to the parasite's tegument, a complex syncytial outer layer essential for nutrient absorption, waste excretion, and protection against the host's immune system [6, 7]. TAL proteins are thought to play critical roles in calcium-mediated signaling and vesicle transport within the tegument, which is vital for the parasite's survival and development [6, 9, 10]. In the context of disease, TAL proteins are significant because they are major targets of the human immune response [2, 3]. Specifically, IgE antibodies directed against certain TAL members, such as SmTAL1 (Sm22.6), are strongly associated with the development of protective immunity in individuals living in endemic areas [4, 12]. This makes them promising candidates for vaccine development [6, 10]. Furthermore, biochemical studies have shown that some TAL proteins, particularly SmTAL1, interact with the frontline anti-schistosomal drug praziquantel, suggesting they may be involved in the drug's mechanism of action or represent direct therapeutic targets [8, 10]. Other small molecules, including calmodulin antagonists like trifluoperazine, also bind to these proteins, offering potential avenues for novel drug discovery against schistosomiasis [8, 10].
Drugs such as praziquantel and various calmodulin antagonists bind directly to members of the TAL protein family, potentially disrupting calcium-dependent regulatory processes, tegumental transport, or structural integrity of the parasite's outer layer [8, 10].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Schistosome Tegument-Allergen-Like protein family (TAL family).